ClinicalTrials.gg
CompletedNCT01227499Updated May 5, 2014

Differential Diagnosis of STA-PSV in Thyrotoxicosis

An observational study in Thyrotoxicosis, Peak Systolic Velocity of Superior Thyroid Artery and Thyroiditis, sponsored by xiaolong zhao. Completed at 1 site in China. Open to participants aged 15 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-05-05.

Sponsored by xiaolong zhao · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
169
Ages
15 Years to 85 Years
Sex
All
01

Study summary

Aim: Graves's disease and thyroiditis can both characterized with thyrotoxicosis, but their clinical outcome and therapy is quiet different. Measurement of iodine uptake is the gold standard to differential diagnosis the thyroiditis or Graves's disease. But the iodine uptake is limited for its availability in china and easily influenced by medicine or food contained iodine.The blood pattern of thyroid CFDS is useful for differentiate the cause of thyrotoxicosis.Most previous studies using the descriptive pattern of thyroid CFDS is easily varied by operator subjective judgement. This study is focus on the role of peak systolic velocity of thyroid superior artery in differential diagnosis of thyrotoxicosis. Methods: Patients with thyrotoxicosis symptoms without recent medicine history were enrolled in two clinical center. Its thyroid function, iodine uptake , CFDS of thyroid and peak systolic velocity of thyroid superior artery is detected. Thyrotoxicosis is defined as TSH level below the low value of normal range. Graves disease is defined as the typical symptoms of graves disease such as graves ophthalmopathy or increased iodine uptake. Thyroiditis is defined as lack of typical symptoms of graves disease or decreased iodine uptake.We use receiver operator curve(ROC) to evaluate its diagnosis value

02

Conditions studied

  • Thyrotoxicosis
  • Peak Systolic Velocity of Superior Thyroid Artery
  • Thyroiditis
  • Graves Disease
03

In context

Thyrotoxicosis

21 studies on the registry are indexed under Thyrotoxicosis; 5 are open to participants now.

This study's enrollment of 169 is above the median of 66 across 13 observational studies indexed under Thyrotoxicosis.

Browse Thyrotoxicosis studies →

Lead sponsor

xiaolong zhao is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • newly diagnosed without taking any antithyroid drug or beta receptor blocker with TSH level below the lower limits of reference range
  • is willing to be enrolled

Exclusion criteria

Exclusion Criteria:

  • unwilling
  • taking antithyroid drug or beta receptor blocker
  • taking foods or medicine rich in iodine in 8 weeks
  • women with pregnant or lactation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
169 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. mean STA-PSV

    the mean STA-PSV

    Time frame: 2014-04-07

  2. uptake of iodine

    Time frame: December 1, 2013

Secondary outcomes

  1. PSV

    Time frame: December 1, 2013

Other outcomes

  1. thyroid funciton

    Time frame: December 1, 2013

07

Study locations

1 site
  • Xiaolong Zhao
    Shanghai, Shanghai 200040, China
08

References and documents

Publications

  • Zhao X, Chen L, Li L, Wang Y, Wang Y, Zhou L, Zeng F, Li Y, Hu R, Liu H. Peak systolic velocity of superior thyroid artery for the differential diagnosis of thyrotoxicosis. PLoS One. 2012;7(11):e50051. doi: 10.1371/journal.pone.0050051. Epub 2012 Nov 16. PubMed 23166817 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Oct 25, 2010
Start
Jun 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Last update
May 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01227499
Lead sponsor
xiaolong zhao
Responsible party
xiaolong zhao (endocrinology department, Huashan Hospital) — Sponsor-investigator
First posted
Oct 25, 2010
Start date
Jun 2010
Primary completion
Nov 2011
Completion
Nov 2011
Last update
May 5, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion